Quintrio
Home

PHARMACEUTICAL PREPARATIONS

BioAge Labs, Inc. Common Stock

BIOA

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.

Last trade $5.12
Day change -$0.105 (-2.01%)
Day range $5.01 – $5.33
Volume 250,395
Market cap $240M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$239.86M
Price / earnings
—
Price / book
0.69×
Price / sales
27.89×
EV / sales
21.77×
EV / EBITDA
-1.56×

Profitability

Earnings per share
-$2.35
Return on assets
-29.32%
Return on equity
-31.12%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
15.51×
Quick ratio
15.51×
Cash ratio
2.77×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$103M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BIOA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$298K$2.45M$2.77M$3.08M$2.05M$2.41M$1.45M$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$298K$2.45M$2.77M$3.08M$2.05M$2.41M$1.45M$0
Selling, general and administrative$7.48M$7.42M$7.74M$7M$6.68M$7.34M$6.79M$6.14M
Research and development$30.23M$24.37M$20.41M$24.5M$18.51M$19.84M$11.11M$19.23M
Total operating expenses$37.71M$31.78M$28.15M$31.5M$25.19M$27.18M$17.9M$25.36M
Operating income-$37.41M-$29.33M-$25.38M-$28.42M-$23.14M-$24.77M-$16.45M-$25.36M
Interest expense$0-$1K-$39K-$92K-$149K-$201K-$255K-$319K
Income before taxes-$33.5M-$26.1M-$22.25M-$25.94M-$20.17M-$21.56M-$12.93M-$21.13M
Income taxes$0$0$0$0$0$0$0$0
Net income-$33.5M-$26.1M-$22.25M-$25.94M-$20.17M-$21.56M-$12.93M-$21.13M
Net income attributable to common shareholders-$33.5M-$26.1M-$22.25M-$25.94M-$20.17M-$21.56M-$12.93M-$21.13M
EBITDA-$37.33M-$29.26M-$25.31M-$28.35M-$23.09M-$24.71M-$16.41M-$25.32M
Basic earnings per share-$0.73-$0.58-$0.52-$0.72-$0.56-$0.60-$0.36-$0.59
Diluted earnings per share-$0.73-$0.58-$0.52-$0.72-$0.56-$0.60-$0.36-$0.59

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

BioAge Labs, Inc. (BIOA) Reports Q3 Loss, Misses Revenue Estimates

BioAge Labs (BIOA) reported a quarterly loss of $0.73 per share, missing consensus estimates by 7.35%, with revenues of $0.3 million falling 66.89% short of expectations. The company's stock has declined 55% year-to-date, and it received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions. The Medical - Biomedical and Genetics industry ranks in the top 45% of sectors.

GlobeNewswire Inc.

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor, in patients with elevated cardiovascular risk and systemic inflammation. Topline data is anticipated in the second half of 2026. The company also announced participation in three upcoming investor conferences in September 2026.

GlobeNewswire Inc.

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

BioAge Labs announced the first participant dosing in QUELL-CV, a Phase 2 trial of BGE-102, an oral NLRP3 inhibitor for patients with obesity and elevated inflammation. Phase 1 data showed BGE-102 achieved up to 98% suppression of IL-1β and 86% median hsCRP reductions. The company also plans to initiate QUELL-DME trial in diabetic macular edema in mid-2026. BioAge reported Q2 2026 net loss of $26.1 million with $381.3 million in cash, sufficient to fund operations through 2029.

GlobeNewswire Inc.

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

BioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor for cardiovascular risk reduction. The randomized, double-blind, placebo-controlled trial will enroll approximately 160 participants with obesity and elevated inflammation across three dose levels. Phase 1 results showed BGE-102 achieved median hsCRP reductions of 86% and was well tolerated. Topline data are anticipated in the second half of 2026, with an additional Phase 1b/2a trial in diabetic macular edema planned for mid-2026.

GlobeNewswire Inc.

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs, a clinical-stage biotechnology company, announced it will participate in the Jefferies Global Healthcare Conference (June 3-4, 2026) and Goldman Sachs Global Healthcare Conference (June 8-10, 2026). Company executives will present and hold one-on-one meetings at both events. BioAge is developing BGE-102, an NLRP3 inhibitor for cardiometabolic diseases, with Phase 2 cardiovascular data expected by end of 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.